TREATMENT OF AMYLOIDOGENIC DISEASES
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer'"'"'s disease using antibodies to Aβ. The invention also provides monitoring regimes that as can assess changes in symptoms or signs of the patient following treatment.
-
Citations
114 Claims
-
1-2. -2. (canceled)
-
3. A method of therapeutically treating Alzheimer'"'"'s disease, comprising administering by intravenous infusion to a patient suffering from the disease a dosage of an antibody that specifically binds to an N-terminal fragment of beta amyloid peptide (Aβ
- ) with a binding affinity of at least 107 M−
1, and monitoring the patient for posterior reversible encephalopathy syndrome (PRES) or vascular edema. - View Dependent Claims (5, 6, 7, 18, 27, 28, 29, 31, 32, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)
- ) with a binding affinity of at least 107 M−
-
4. (canceled)
-
8-17. -17. (canceled)
-
19-26. -26. (canceled)
-
30. (canceled)
-
33-44. -44. (canceled)
-
56. (canceled)
-
57. A method of treating Alzheimer disease, comprising:
administering to a patient having the disease an antibody that specifically binds to an N-terminal fragment of Aβ
in a regime sufficient to maintain an average serum concentration of the antibody in the patient in a range of 1-15 μ
g antibody/ml serum and thereby treating the patient.
-
58-94. -94. (canceled)
-
95. A method of treating Alzheimer disease, comprising:
administering to a patient having the disease an antibody that specifically binds to an N-terminal fragment of Aβ
in a regime sufficient to maintain a maximum serum concentration of the antibody in the patient less than about 28 μ
g antibody/ml serum and thereby treating the patient.- View Dependent Claims (111, 112, 113)
-
96-100. -100. (canceled)
-
101. A method of treating Alzheimer disease, comprising:
administering to a patient having the disease an antibody that specifically binds to an N-terminal fragment of Aβ
in a regime sufficient to maintain an average serum concentration of the antibody in the patient below about 7 μ
g antibody/ml serum and thereby treat the patient.
-
102-110. -110. (canceled)
-
114-115. -115. (canceled)
Specification